Kathy L Hibbs has sold stock and made no open-market buys since Dec 2022

Kathy L. Hibbs, J.D., is an accomplished healthcare technology executive and corporate director with more than two decades of experience in healthcare and genomics.( She serves as a non-executive director on the board of SOPHiA GENETICS SA, where she was appointed to the Board of Directors and its Audit Committee in 2021, and has recently traded as a director-level insider in the company’s securities.( Hibbs is also a member of the Board of Directors of Standard BioTools Inc., reflecting her ongoing leadership presence across the life sciences and diagnostics sectors.(

From 2014 to 2024, Hibbs held senior executive roles at 23andMe, Inc., first as Chief Legal and Regulatory Officer and later as Chief Administrative Officer, where she led complex legal operations and regulatory affairs and helped pioneer the first FDA clearance for over‑the‑counter genetic testing.( Earlier in her career, she spent 15 years as an executive officer and corporate secretary at public biotechnology companies Genomic Health, Inc. and Monogram Biosciences, Inc., and served on the leadership team of Varian Medical Systems, Inc., developing deep expertise in legal, compliance, and business development for personalized medicine.( Regularly recognized as one of the Bay Area’s most influential women by the San Francisco Business Times and Silicon Valley Business Journal, and ranked by Chambers among the most influential general counsel in the United States, Hibbs has also served on the boards of Decipher Biosciences, Inc. and Cadex Genomics, Inc.(

Written by Perplexity from public sources.